Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185155 | 0.82 | — | — | |
| SCHEMBL29936230 | 0.82 | — | — | |
| Propionic Acid SCHEMBL28741996 | 0.81 | FFAR3 (0.32) | HCAR2 | |
| Hydrochloric Acid SCHEMBL30870490 | 0.80 | — | — | |
| Ethyl Propionate SCHEMBL28742006 | 0.72 | PKM (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL17893829 | 0.69 | KMT2A (0.33) | L3MBTL1HCAR2 | |
| Trifluoroacetic Acid SCHEMBL13822271 | 0.68 | GPR6 (0.35) | L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL4108467 | 0.66 | MAPT (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL15543969 | 0.65 | CLK1 (0.41) | L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL23457501 | 0.63 | HCAR2 (0.35) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028347-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | L3MBTL1 1994/4885HCAR2 142/4885 |
| US-20240132509-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HCN3, TRPV1 | L3MBTL1 3821/4885HCAR2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.